Haleon Upgrades 2022 Views After 3Q Revenue Rose on Pricing, Volumes
2022年11月10日 - 04:54PM
Dow Jones News
By Michael Susin
Haleon PLC said Thursday that organic revenue for the third
quarter rose, driven by increased pricing and higher volumes.
The consumer-healthcare business, which was spun out of GSK PLC
and is partly owned by Pfizer Inc., reported a 10% rise in revenue
for the quarter to 2.89 billion pounds ($3.28 billion). For the
nine-month period, revenue rose 14% on year to GBP8.08 billion.
"Respiratory performance was strong given sustained incidences
of Covid and cold and flu combined with successful innovation", it
added.
Haleon--which houses Sensodyne toothpaste and Aquafresh
mouthwash as well as over-the-counter medicines Panadol and
Advil--upgraded its full-year guidance and currently expects
organic revenue growth to be in the range of 8% and 8.5% compared
with a previous range of between 6% and 8%.
Its margin of adjusted operating profit--which strips out
exceptional and other one-off items is currently expected to be
slightly above last year's margin of 22.8%, driven by positive
foreign-exchange movements.
GSK owns 13.5% of Haleon, while Pfizer owns 32%.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
November 10, 2022 02:39 ET (07:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Haleon (LSE:HLN)
過去 株価チャート
から 2 2024 まで 3 2024
Haleon (LSE:HLN)
過去 株価チャート
から 3 2023 まで 3 2024